Gilead Sciences, Inc.

Key catalysts

• HIV franchise durability

  Biktarvy leadership and Yeztugo adoption can sustain treatment and prevention growth.

• Oncology expansion

  Trodelvy demand and acquired cell-therapy and antibody-drug-conjugate assets can diversify the portfolio.

• Liver-disease growth

  Livdelzi uptake can add a new growth leg alongside established antiviral franchises.

Principal risks

• HIV concentration

  Heavy reliance on HIV leaves earnings exposed to competition, payer pressure and patent transitions.

• Acquisition and IPR&D

  Large acquisitions and acquired research charges can consume capital without producing approved products.

• Cell-therapy competition

  Manufacturing complexity and intense competition can pressure patient access and cell-therapy sales.

Gilead's first-quarter 2026 results showed growth in its base business led by HIV, Trodelvy and Livdelzi, with Yeztugo launch progress and substantial pipeline investment and acquisition activity.

Valuation interpretation

• HIV cash-flow durability provides support, but a higher growth interpretation requires successful diversification into prevention, oncology and liver disease.
• Pipeline value should be weighed against acquisition spending, clinical attrition and the timing of patent erosion.